Antengene Corp., a hematology and oncology-focused biopharmaceutical company, has closed $97 million in Series C financing to support continued clinical development of its pipeline of hematology and oncology therapies, expanding in-house R&D capabilities and commercial infrastructures in APAC markets. Antengene has a pipeline of six clinical-stage programs and six preclinical stage oncology assets:
ATG-010 (selinexor) is the first and only oral selective inhibitor of nuclear export (SINE). In July 2019, the U.S. FDA approved selinexor in combination with low-dose dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM). In June 2020, selinexor was approved by the U.S. FDA as a treatment for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Clinical trials of ATG-010 in RRMM and R/R DLBCL are ongoing in China. The compound is also in late clinical development for various other hematologic malignancies and solid tumors (including KRAS mutant tumors).
ATG-008 (onatasertib) is a second-generation dual mTORC1/2 inhibitor being studied in clinical trials for the treatment of advanced hepatocellular carcinoma (HCC), as well as non-small-cell lung cancer (NSCLC), gynecological malignancies and other cancers as a single agent or in combination with an anti-PD-1 antibody.
ATG-016 (eltanexor) is a second-generation oral selective inhibitor of nuclear export protein XPO1 being studied in myelodysplastic syndrome (MDS) as well as various types of solid tumors, such as colorectal cancer (CRC) and prostate cancer (PrC).
ATG-019 is a first-in-class PAK4/NAMPT dual-target inhibitor being studied in clinical trials in non-Hodgkin's lymphoma (NHL), colorectal cancer, NSCLC, and melanoma. Preclinical studies have demonstrated that ATG-019 in combination with anti-PD-1 antibodies can effectively improve the anti-tumor activity and is effective in treating patients that become resistant to anti-PD-1 therapy.
ATG-527 (verdinexor) is being studied as a potential treatment for anti-viral infection and autoimmune diseases – such as Epstein-Barr virus (EBV), respiratory syncytial virus (RSV) infection, cytomegalovirus (CMV) infection, systemic lupus erythematosus (SLE).
ATG-017 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor in clinical development for the treatment of various solid tumors, non-Hodgkin's lymphoma, acute myeloid leukemia (AML) and multiple myeloma.